Market Summary
USD1.210.00
Delayedas of 02 Oct 2023, 11:40 am0.00%
PSNL Stock Price
PSNL RSI Chart
PSNL Valuation
PSNL Price/Sales (Trailing)
PSNL Profitability
PSNL Fundamentals
PSNL Revenue
PSNL Earnings
Price Action
52 Week Range
1.174.31
(Low)(High)
Last 7 days
-2.4%
Last 30 days
-26.2%
Last 90 days
-35.6%
Trailing 12 Months
-58.7%
PSNL Financial Health
PSNL Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for PSNL
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-07-31 | Tachibana Aaron | sold | -1,496 | 2.26 | -662 | cfo and coo |
2023-07-31 | Chen Richard | sold | -1,096 | 2.26 | -485 | chief medical officer and evp |
2023-06-16 | Chen Richard | sold | -9,971 | 2.07 | -4,817 | chief medical officer and evp |
2023-06-16 | Tachibana Aaron | sold | -14,291 | 2.07 | -6,904 | cfo and coo |
2023-06-16 | Moore Stephen Michael | sold | -3,123 | 2.07 | -1,509 | general counsel |
2023-05-17 | Tachibana Aaron | sold | -2,750 | 1.98 | -1,389 | cfo and coo |
2023-05-17 | Chen Richard | sold | -1,922 | 1.98 | -971 | chief medical officer and evp |
2023-05-17 | Moore Stephen Michael | sold | -3,526 | 1.98 | -1,781 | general counsel |
2023-05-02 | Moore Stephen Michael | sold | -11,683 | 2.29 | -5,102 | general counsel |
2023-03-17 | Tachibana Aaron | sold | -11,164 | 2.83 | -3,945 | cfo and coo |
Which funds bought or sold PSNL recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | reduced | -40.39 | -123,000 | 85,000 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 4.38 | -4,747 | 11,673 | -% |
2023-08-15 | Bragg Financial Advisors, Inc | new | - | 23,771 | 23,771 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | reduced | -37.41 | -119,661 | 88,937 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 5.75 | -201 | 519 | -% |
2023-08-14 | Engineers Gate Manager LP | sold off | -100 | -35,720 | - | -% |
2023-08-14 | STATE STREET CORP | unchanged | - | -114,613 | 244,855 | -% |
2023-08-14 | Tower Research Capital LLC (TRC) | reduced | -66.45 | -21,707 | 6,293 | -% |
2023-08-14 | AMERIPRISE FINANCIAL INC | reduced | -19.83 | -178,915 | 215,241 | -% |
2023-08-14 | D. E. Shaw & Co., Inc. | added | 2.65 | -337,815 | 785,205 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Personalis
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jan 31, 2023 | blackrock inc. | 7.7% | 3,558,913 | SC 13G/A | |
| Jan 25, 2023 | jpmorgan chase & co | 7.6% | 3,502,353 | SC 13G/A | |
| Mar 09, 2022 | blackrock inc. | 10.0% | 4,502,224 | SC 13G/A | |
| Mar 07, 2022 | lightspeed venture partners viii lp | 9.16% | 4,117,768 | SC 13D/A | |
| Feb 09, 2022 | ark investment management llc | 10.91% | 4,888,115 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 9.8% | 4,389,333 | SC 13G/A | |
| Jan 14, 2022 | jpmorgan chase & co | 9.5% | 4,267,659 | SC 13G/A | |
| Feb 16, 2021 | abingworth llp | 0.0% | 0 | SC 13G/A | |
| Feb 02, 2021 | blackrock inc. | 5.9% | 2,309,401 | SC 13G | |
| Jan 15, 2021 | jpmorgan chase & co | 8.5% | 3,340,089 | SC 13G |
Recent SEC filings of Personalis
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 28, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 10-Q | Quarterly Report | |
| Aug 02, 2023 | 4 | Insider Trading | |
| Aug 02, 2023 | 4 | Insider Trading |
Peers (Alternatives to Personalis)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
IQV | 36.0B | 14.7B | -12.38% | 8.34% | 32.87 | 2.45 | 3.86% | -5.52% |
A | 32.8B | 7.0B | -8.85% | -8.74% | 28.92 | 4.68 | 5.03% | -14.68% |
ILMN | 21.7B | 4.5B | -17.33% | -29.17% | -5.18 | 4.86 | -4.92% | -21931.58% |
CRL | 10.0B | 4.2B | -6.53% | 3.14% | 20.76 | 2.4 | 13.29% | 9.18% |
| MID-CAP | ||||||||
MEDP | 7.4B | 1.7B | -10.66% | 55.07% | 27.54 | 4.42 | 30.05% | 28.37% |
SYNH | 4.5B | 5.4B | 1.03% | -7.57% | 62.57 | 0.82 | 0.01% | -74.39% |
| SMALL-CAP | ||||||||
PACB | 2.1B | 146.1M | -25.51% | 49.11% | -6.55 | 14.31 | 4.72% | -55.19% |
ADPT | 788.3M | 189.6M | -20.20% | -20.44% | -4.13 | 4.16 | 18.74% | 17.75% |
CSTL | 452.4M | 167.5M | -15.17% | -33.56% | -5.09 | 2.7 | 52.01% | -99.69% |
NVTA | 159.7M | 493.9M | -38.63% | -74.68% | -0.2 | 0.32 | -1.39% | 74.28% |
CDXS | 131.9M | 99.2M | 7.39% | -69.07% | -2.33 | 1.33 | -26.56% | -199.52% |
PSNL | 58.7M | 67.1M | -26.22% | -58.70% | -0.53 | 0.87 | -12.13% | -17.68% |
Personalis News
Returns for PSNL
Cumulative Returns on PSNL
-62.0%
3-Year Cumulative Returns
Risks for PSNL
What is the probability of a big loss on PSNL?
99.1%
Probability that Personalis stock will be more than 20% underwater in next one year
97.8%
Probability that Personalis stock will be more than 30% underwater in next one year.
96.4%
Probability that Personalis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does PSNL drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Personalis was unfortunately bought at previous high price.
Drawdowns
Financials for Personalis
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -2.2% | 67,139,000 | 68,680,000 | 65,047,000 | 69,007,000 | 76,410,000 | 79,840,000 | 85,494,000 | 84,988,000 | 82,543,000 | 80,368,000 | 78,648,000 | 76,626,000 | 73,963,000 | 70,293,000 | 65,207,000 | 60,210,000 | 54,711,000 | 47,685,000 | 37,774,000 | 32,822,667 | 25,926,000 |
| S&GA Expenses | -6.0% | 58,840,000 | 62,580,000 | 63,969,000 | 59,850,000 | 57,209,000 | 52,763,000 | 47,698,000 | 44,909,000 | 40,562,000 | 36,839,000 | 33,692,000 | 29,160,000 | 27,423,000 | 25,184,000 | 22,080,000 | 19,388,000 | 15,990,000 | 13,128,000 | 11,271,000 | 10,524,000 | 10,416,000 |
| R&D Expenses | 2.4% | 65,951,000 | 64,387,000 | 64,912,000 | 62,855,000 | 61,515,000 | 56,914,000 | 49,312,000 | 43,320,000 | 36,896,000 | 31,674,000 | 28,568,000 | 27,421,000 | 25,531,000 | 23,563,000 | 22,418,000 | 19,326,000 | 17,597,000 | 16,600,000 | 14,304,000 | 14,148,000 | 14,000,000 |
| EBITDA | 100.0% | - | -104,073,000 | -104,642,000 | -95,129,000 | -86,666,000 | -74,450,000 | -59,014,000 | -52,287,333 | -44,249,333 | -38,661,000 | -35,463,000 | -28,873,000 | -26,313,000 | -22,484,000 | -19,194,000 | -16,247,000 | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -1.52 | -1.61 | -1.38 | -1.13 | -0.93 | -0.69 | -0.62 | -0.54 | -0.48 | -0.45 | -0.38 | -0.36 | -0.32 | -0.29 | -0.27 | - | - | - | - | - |
| Interest Expenses | -5.8% | 178,000 | 189,000 | 201,000 | 213,000 | 228,000 | 243,000 | 184,000 | 166,667 | 86,667 | - | 2,000 | 2,000 | 206,000 | 951,000 | 1,133,000 | 1,377,000 | 1,628,000 | 1,456,000 | 1,894,000 | 2,056,000 | 2,292,000 |
| Earnings Before Taxes | 3.2% | -110,105,000 | -113,718,000 | -113,275,000 | -102,417,000 | -93,594,000 | -81,007,000 | -65,212,000 | -58,333,000 | -50,215,000 | -44,521,000 | -41,223,000 | -34,541,000 | -31,885,000 | -28,501,000 | -25,075,000 | -21,987,000 | -18,742,000 | -20,189,000 | -19,879,000 | -21,906,000 | -29,256,000 |
| EBT Margin | 100.0% | - | -1.66 | -1.74 | -1.48 | -1.22 | -1.01 | -0.76 | -0.69 | -0.61 | -0.55 | -0.52 | -0.45 | -0.43 | -0.41 | -0.38 | -0.37 | - | - | - | - | - |
| Net Income | 3.2% | -110,174,000 | -113,765,000 | -113,315,000 | -102,446,000 | -93,624,000 | -81,031,000 | -65,226,000 | -58,368,000 | -50,243,000 | -44,545,000 | -41,280,000 | -34,584,000 | -31,924,000 | -28,538,000 | -25,084,000 | -21,994,000 | -18,750,000 | -20,196,000 | -19,886,000 | -21,774,666 | -25,380,000 |
| Net Income Margin | 100.0% | - | -1.66 | -1.74 | -1.48 | -1.23 | -1.01 | -0.76 | -0.69 | -0.61 | -0.55 | -0.52 | -0.45 | -0.43 | -0.41 | -0.38 | -0.37 | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -119,661,000 | -120,129,000 | -112,680,000 | -97,343,000 | -89,720,000 | -81,911,000 | -66,429,000 | -63,265,000 | -49,362,000 | -45,899,000 | -42,038,000 | -37,666,000 | -34,276,000 | -26,451,000 | -24,411,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
| Assets | -8.5% | 249 | 272 | 293 | 318 | 358 | 381 | 397 | 407 | 383 | 396 | 245 | 249 | 146 | 152 | 157 | 160 | 192 | 42.00 |
| Current Assets | -11.9% | 161 | 183 | 200 | 222 | 260 | 294 | 318 | 329 | 354 | 373 | 221 | 224 | 120 | 135 | 140 | 140 | 176 | 30.00 |
| Cash Equivalents | 11.5% | 97.00 | 87.00 | 89.00 | 84.00 | 87.00 | 92.00 | 106 | 80.00 | 70.00 | 137 | 69.00 | 133 | 25.00 | 47.00 | 55.00 | 87.00 | 163 | 20.00 |
| Net PPE | -3.2% | 59.00 | 61.00 | 62.00 | 61.00 | 48.00 | 31.00 | 20.00 | 18.00 | 14.00 | 11.00 | 12.00 | 13.00 | 13.00 | 13.00 | 14.00 | 15.00 | 13.00 | 11.00 |
| Liabilities | -7.1% | 73.00 | 79.00 | 75.00 | 75.00 | 93.00 | 94.00 | 86.00 | 81.00 | 45.00 | 47.00 | 50.00 | 45.00 | 52.00 | 53.00 | 51.00 | 48.00 | 75.00 | 59.00 |
| Current Liabilities | -16.3% | 29.00 | 34.00 | 33.00 | 34.00 | 42.00 | 40.00 | 31.00 | 27.00 | 34.00 | 39.00 | 41.00 | 36.00 | 43.00 | 52.00 | 50.00 | 47.00 | 56.00 | 58.00 |
| Shareholder's Equity | -9.1% | 176 | 194 | 218 | 242 | 265 | 287 | 310 | 325 | 339 | 348 | 195 | 204 | 93.00 | 99.00 | 107 | 111 | 117 | - |
| Retained Earnings | -6.2% | -413 | -389 | -360 | -329 | -302 | -275 | -247 | -226 | -209 | -194 | -181 | -168 | -158 | -149 | -140 | -133 | -127 | -115 |
| Additional Paid-In Capital | 1.1% | 589 | 583 | 579 | 573 | 569 | 563 | 558 | 552 | 548 | 543 | 377 | 372 | 252 | 249 | 247 | 245 | 244 | 9.00 |
| Shares Outstanding | 3.7% | 49.00 | 47.00 | 47.00 | 46.00 | 46.00 | 45.00 | 45.00 | 45.00 | 44.00 | 42.00 | 39.00 | 35.00 | 32.00 | 31.00 | 18.00 | 14.00 | 5.00 | 3.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 22.7% | -57.69 | -74.62 | -70.23 | -68.74 | -71.86 | -70.44 | -70.83 | -58.09 | -56.33 | -45.75 | -42.65 | -37.72 | -31.23 | -26.78 | -18.07 | -17.27 | -8.06 | 4.00 | 6.00 | -1.72 | 6.00 |
| Share Based Compensation | -5.1% | 17.00 | 18.00 | 19.00 | 18.00 | 17.00 | 16.00 | 14.00 | 14.00 | 12.00 | 10.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 4.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 |
| Cashflow From Investing | -5.0% | 66.00 | 69.00 | 53.00 | 71.00 | 89.00 | 19.00 | -60.07 | -163 | -187 | -147 | -65.14 | -36.85 | -86.43 | -80.65 | -81.58 | -47.40 | -5.42 | -4.77 | -7.85 | -7.78 | -10.47 |
| Cashflow From Financing | - | 3.00 | - | 1.00 | 2.00 | 1.00 | 7.00 | 170 | 169 | 288 | 284 | 121 | 121 | -20.57 | 121 | 135 | 135 | 157 | 19.00 | -0.59 | -0.90 | -0.81 |
PSNL Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 16,699 | $ 18,240 | $ 35,559 | $ 33,467 |
| Costs and expenses | ||||
| Cost of revenue | 11,907 | 13,959 | 26,037 | 24,908 |
| Research and development | 17,852 | 16,288 | 34,425 | 33,386 |
| Selling, general and administrative | 12,134 | 15,874 | 26,231 | 31,360 |
| Restructuring and other charges | 152 | 4,037 | ||
| Total costs and expenses | 42,045 | 46,121 | 90,730 | 89,654 |
| Loss from operations | (25,346) | (27,881) | (55,171) | (56,187) |
| Interest income | 1,465 | 349 | 2,718 | 493 |
| Interest expense | (39) | (50) | (86) | (109) |
| Other income (expense), net | 1 | 50 | (25) | 69 |
| Loss before income taxes | (23,919) | (27,532) | (52,564) | (55,734) |
| Provision for income taxes | 36 | 14 | 50 | 21 |
| Net loss | $ (23,955) | $ (27,546) | $ (52,614) | $ (55,755) |
| Net loss per share, basic | $ (0.50) | $ (0.60) | $ (1.11) | $ (1.23) |
| Net loss per share, diluted | $ (0.50) | $ (0.60) | $ (1.11) | $ (1.23) |
| Weighted-average shares outstanding, basic | 47,669,513 | 45,637,838 | 47,204,891 | 45,316,795 |
| Weighted-average shares outstanding, diluted | 47,669,513 | 45,637,838 | 47,204,891 | 45,316,795 |
PSNL Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 97,195 | $ 89,128 |
| Short-term investments | 40,012 | 78,530 |
| Accounts receivable, net | 10,132 | 16,642 |
| Inventory and other deferred costs | 8,140 | 8,591 |
| Prepaid expenses and other current assets | 5,476 | 6,808 |
| Total current assets | 160,955 | 199,699 |
| Property and equipment, net | 59,486 | 61,935 |
| Operating lease right-of-use assets | 24,660 | 26,480 |
| Other long-term assets | 3,937 | 4,586 |
| Total assets | 249,038 | 292,700 |
| Current liabilities | ||
| Accounts payable | 8,847 | 12,854 |
| Accrued and other current liabilities | 16,408 | 19,013 |
| Contract liabilities | 3,337 | 1,264 |
| Total current liabilities | 28,592 | 33,131 |
| Long-term operating lease liabilities | 40,326 | 41,041 |
| Other long-term liabilities | 4,034 | 389 |
| Total liabilities | 72,952 | 74,561 |
| Commitments and Contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Common stock, $0.0001 par value - 200,000,000 shares authorized; 48,507,101 and 46,707,084 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 5 | 5 |
| Additional paid-in capital | 589,418 | 579,456 |
| Accumulated other comprehensive loss | (313) | (912) |
| Accumulated deficit | (413,024) | (360,410) |
| Total stockholders’ equity | 176,086 | 218,139 |
| Total liabilities and stockholders’ equity | $ 249,038 | $ 292,700 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.